 |
 |
|
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
| |
| | |
|
|
Official Journal of the European Federation for Pharmaceutical Sciences (EUFEPS)
|
|
|
|
Guide for Authors
1.1. Manuscripts
Authors should submit their manuscript electronically via the homepage of this journal ( http://www.elsevier.com/journals).
After registration, authors will be asked to upload their manuscript and associated artwork. Full instructions on how to use the
online submission tool are available at the web address listed above.
Manuscripts submitted to the journal are accepted on the understanding
that: (1) they are subject to editorial review, (2) they have not been and will not be published in whole or in part in any other journal
and (3) the recommendations of the Declarations of Helsinki and Tokyo, for humans, and the European Community guidelines as accepted
principles for the use of experimental animals, have been adhered to. The European Journal of Pharmaceutical Sciences will,
therefore, only consider manuscripts that describe experiments which have been carried out under approval of an institutional or local
ethics committee. Only manuscripts written in English should be submitted.
1.2. Format
Manuscripts should be neatly typed,
double-spaced throughout, including tables, with at least 2.5 cm margins on all sides. Use one font type and size throughout the manuscript.
Author(s) should not break or hyphenate words. The manuscript should be submitted with a cover letter containing the declaration that
the study was performed according to the international, national and institutional rules considering animal experiments, clinical studies
and that the protocol complies with the particular recommendation and that approval of their protocols was obtained.
Webster's New
International Dictionary or the Oxford English Dictionary should be consulted for spelling. Latin plurals should not be used if the English
equivalent has become the accepted form, e.g., formulas not formulae. Use of hyphens, capital letters, numbers written or spelled out
(e.g., 8 or eight) should be consistent throughout the manuscript. Words at the end of a line should not be divided.
1.3. Electronic
manuscripts
Ensure that the letter "l" and digit "1" (also letter "O" and digit "0") have been used properly, and format your
article (tabs, indents, etc.) consistently. Characters not available on your word processor (Greek letters, mathematical symbols, etc.)
should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter α). Such codes should be
used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your word processor to
introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and,
in particular, the reference style of the journal. If your word processor features the option to save files "in flat ASCII", please do not use it.
LaTeX documents
If the LaTeX file is suitable, proofs will be produced without rekeying the text. The article
should preferably be written using Elsevier's document class "elsart" or, alternatively, the standard document class "article".
The
Elsevier LaTeX package (including detailed instructions for LaTeX preparation) can be obtained from the Quickguide: http://www.elsevier.com/latex.
It consists of the files: elsart.cls, guidelines for users of elsart, a template file for quick start, and the instruction booklet "Preparing
articles with LaTeX".
Additional instructions on how to prepare your manuscript can be found at Elsevier's Quickguide: http://www.elsevier.com.
For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions.
1.4. Abbreviations
Abbreviations are a hindrance for the reader. Use as few abbreviations as possible and write out names
of compounds, receptors, etc., in full throughout the text of the manuscript, with the exceptions given below. Unnecessary and nonsense
abbreviations are not allowed. Generic names should not be abbreviated. As an example, AMP, HAL, HIST, RAMH, TAM, SST, for amphetamine,
haloperidol, histamine, (R)-α -methylhistamine, tamoxifen, somatostatin, are not accepted. Abbreviations which have come to replace
the full term (e.g., GABA, DOPA, PDGF, 5-HT, for Υ -aminobutyric acid, 3,4-dihydroxyphenylalanine, PDGF, 5-hydroxytryptamine) may
be used, provided the term is spelled out in the abstract and in the body of the manuscript the first time the abbreviation is used.
Unwieldy chemical names may be abbreviated. As an example, 8-OH-DPAT, DOI, DTG, BAPTA, for 8-hydroxy-2-(di-n-propylamino)tetralin,
1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, 1,3-di(2-tolyl)-guanidine, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic
acid, are acceptable; however, the full chemical name should be given once in the body of the manuscript and in the abstract, followed
in both cases by the abbreviation. Code names may be used, but the full chemical name should be given in the text and in the abstract. Authors not conforming to these demands may have their manuscripts returned for correction with delayed publication as a result.
Some
abbreviations may be used without definition:
| ADP,CDP, GDP, IDP |
5'-pyrophosphates of
adenosine |
| UDP |
cytidine, guanosine, inosine, uridine |
| AMP etc. |
adenosine 5'-monophosphate
etc. |
| ADP etc. |
adenosine 5'-diphosphate etc. |
| ATP etc. |
adenosine 5'-triphosphate etc. |
| CM-cellulose |
carboxymethylcellulose |
| CoA and acetyl-CoA |
coenzyme A and its acyl derivatives |
| DEAE-cellulose |
O-(diethylaminoethyl)-cellulose |
| DNA |
deoxyribonucleic acid |
| EGTA |
ethylene glycol-bis(β-aminoethyl ether)N,N,N',N'-tetraacetic acid |
| FAD |
flavin-adenine
dinucleotide |
| FMN |
flavin mononucleotide |
| GSH, GSSG |
glutathione, reduced and oxidized |
| Hepes |
4-(2-hydroxyethyl)-1-piperazine-ethanesulphonic acid |
| NAD |
nicotinamide-adenine dinucleotide |
| NADP |
nicotinamide-adenine dinucleotide phosphate |
| NMN |
nicotinamide mononucleotide |
| Pi, PPi |
orthophosphate, pyrophosphate |
| RNA |
ribonucleic acid |
| Tris |
2-amino-2-hydroxymethylpropane-1,3-diol |
Two alternative conventions are currently in use in some cases. For example, for the phosphoinositides there are both
the abbreviations recommended by the IUPAC-IUB and those of the Chilton Convention (e.g., PtdIns(4,5)P2 vs. PIP 2for
phosphatidylinositol 4,5-biphosphate). The journal will accept either of these forms but not their combination.
Abbreviations of units
of measurements and other terms are as follows:
Units of mass
| kilogram |
kg |
| gram |
g |
| milligram |
mg |
| microgram |
μg |
| nanogram |
ng |
| mole (gram-molecule) |
mol |
| millimole |
mmol |
| micromole |
μmol |
| nanomole |
nmol |
| picomole |
pmol |
| femtomole |
fmol |
| equivalent |
eq |
Units of time
| hour |
h |
| minute |
min |
| second |
s |
| millisecond |
ms |
| microsecond |
μs |
Units of volume
| litre |
l |
| millilitre |
ml |
| microlitre |
μl |
Units of length
| metre |
m |
| centimetre |
cm |
| millimetre |
mm |
| micrometre |
μm |
| nanometre |
nm |
Units of concentration
| molar (mol/l) |
M |
| millimolar |
mM |
| micromolar |
μM |
| nanomolar |
nM |
| picomolar |
pM |
Units of heat, energy, electricity
| joule |
J |
| degree Celsius (centigrade) |
°C |
| coulomb |
C |
| ampere |
A |
| volt |
V |
| ohm |
Ω |
| siemens |
S |
Units of radiation
| curie |
Ci |
| counts per minute |
cpm |
| disintegrations per minute |
dpm |
| becquerel |
Bq |
Miscellaneous
| gravity |
g
|
| dissociation constant |
K
d
|
| median doses |
LD50, ED50
|
| probability |
P
|
| routes
of drug administration |
i.v., i.p., s.c., i.m. |
| square centimetre |
cm2
|
| standard
deviation |
S.D. |
| standard error of the mean |
S.E.M. |
| Svedberg unit of sedimentation coefficient |
S |
| Hill coefficient |
n
H
|
The isotope mass number should appear before the atomic
symbol, e.g., [3H]noradrenaline, [14C]choline. Ions should be written: Fe3+, Ca2+, Mg2+.
The term absorbance (A) is preferred to extinction or optical density. For abbreviations not included in this list consult: Units,
Symbols and Abbreviations, A Guide for Biological and Medical Authors and Editors, 1994 (The Royal Society of Medicine, London),
ISBN 0-905958-78-0, or Scientific Style and Format. The CBE Manual for Authors, Editors, and Publishers, 6th edn. (Cambridge
University Press, Cambridge), ISBN 0-521-47154-0.
1.5. Nomenclature
Only generic and chemical names of drugs should be used,
although a proprietary equivalent may be indicated once, in parentheses. Pharmacological and Chemical Synonyms, E.E.J. Marler,
9th edn. (Elsevier, Amsterdam, 1990) may be consulted.
The nomenclature of chemical substances should be consistent, clear and unambiguous,
and should conform to the usage of the American Chemical Society and the convention recommended by the International Union of Pure and
Applied Chemistry (IUPAC). When in doubt, writers should consult the indexes of Chemical Abstracts; the various reports and
pamphlets of the American Chemical Society Committee on Nomenclature, Spelling and Pronunciation; and from the International Union of
Biochemistry and Molecular Biology (IUBMB): Biochemical Nomenclature and Related Documents (Portland Press, London).
When
drugs, which are mixtures of stereoisomers are used, the fact that they have a composite nature and the implication of this for interpretation
of the data and drawing of conclusions should be made clear. The use of the appropriate prefix is essential. Use of the generic name
alone without prefix would be taken to refer to agents with no stereoisomers. The nomenclature of the various isomers and isomeric mixtures
can be found in: (i) IUPAC, Nomenclature of Organic Chemistry, eds. J. Rigaudy and S.P. Klesney (Pergamon Press, London), 1979,
p. 481; (ii) Signs of the times: the need for a stereochemically informative generic name system, Simonyi, M., J. Gal and B.
Testa, 1989, Trends Pharmacol. Sci. 10, 349. For nomenclature of peptides, see Neuropeptides, Vol. 1, 1981, p. 231.
The nomenclature
of receptors and their subtypes should conform to the TIPS 1995 Receptor & Ion Channel Nomenclature Supplement (Trends Pharmacol.
Sci. Receptor Nomenclature Supplement 1995). Copies of this supplement are available from the publisher (Elsevier Trends Journals,
Oxford Fulfilment Centre, P.O. Box 800, Kidlington, Oxford OX5 1DX, UK. Tel.: (44-1865) 843-699; Fax: (44-1865) 843-911).
The trivial
name of the enzyme may be used in the text, but the systematic name and classification number according to Enzyme Nomenclature,
rev. edn. (Academic Press, New York, NY, 1984) should be quoted the first time the enzyme is mentioned.
1.6. Editorial review
All manuscripts are generally submitted to 2-3 referees who are chosen for their ability to evaluate the work. Supplementary material
may be included to facilitate the review process. Authors may request that certain referees should not be chosen. Members of the editorial
board will usually be called upon for advice when there is disagreement among the referees or between referees and authors, or when the
editors believe that the manuscript has not received adequate consideration by the referees.
All referees' comments must be responded
to, and suggested changes be made. The author should detail the changes made in response to the referees' comments and suggestions in
an accompanying letter. If the author disagrees with some changes, the reason, supported by data, should be given. The editors may refuse
to publish manuscripts from authors who persistently ignore referees' comments. Handwritten additions or corrections will not be accepted.
Only complete retyping of the pages affected by revision is acceptable. A revised manuscript should be received by the editorial office
no later than 4 months after the editorial decision was sent to the author(s); otherwise it will be processed as a new manuscript.
2. Organization and style of manuscripts
Authors should consult a current issue of the journal for the general manner of presentation.
Manuscripts should be written in clear, concise English (see section 1.1), bearing in mind that English is not the native language of
many of the readers. Terms that are not generally understood should be avoided; however if it is absolutely necessary to use such terms,
they must be defined.
2.1. Research articles
2.1.1. General
The manuscript of a research article should be arranged
as follows.
First page: title, surname(s) and full first name(s) of each author; name and address of the establishment where the work
was done; name, full postal address, telephone and telefax numbers and e-mail of author to whom proofs and other correspondence should
be sent. Next page: abstract and keywords (indexing terms, normally 3-6 items). Pages 3 to end: 1. Introduction; 2. Materials and methods;
3. Results; 4. Discussion; Acknowledgements; References; Tables; Figure legends and Figures. Parts 3 & 4 may be combined into one
item: Results & Discussion. Subdivisions of a section should also be numbered within that section: 2.1., 2.2., 2.3., etc. All pages
should be numbered consecutively, the title page being p. 1. See section 2.7 for further information.
Supplementary material for
electronic publication can be published on the journal website alongside the article. In the print version, a URL reference will be made
to point readers to the location of the article and supplementary material.
2.1.2. Abstract and keywords
The abstract
with keywords should be typed on a separate sheet. The abstract should include: the reason why the experiments were done, a very brief
description of the experiments (including species, tissue, etc.), followed by the main results, and finally, a conclusion giving the
relevance of the results to the question asked. The abstract must be completely self-explanatory. The abstract should not exceed approximately
200 words. No footnotes may be used and a reference, if cited, must be given in full. Standard terms and scientific nomenclature should
be used. Abbreviations and contractions, except those for weights and measures and those explained, should not be used. Below the abstract,
type 3-6 keywords or short phrases suitable for indexing. These terms will be printed at the end of the abstract. If possible, keywords
should be selected from Index Medicus or Excerpta Medica Index.
2.1.3. Introduction, Materials and Methods,
Results, Discussion
The introduction should not be an extensive review of the literature but should refer only to previous work
which has a direct bearing on the topic to be discussed.
Materials and methods should be written clearly and in such detail that the
work can be repeated by others. Procedural detail that has been published previously should be referred to by citation. When a modified
procedure is used, only the author's modifications of the previously published method need to be given in detail.
Results should be
described concisely. Text, tables and figures must be internally consistent.
The discussion should involve the significant findings
presented. Wide digressions are unacceptable because of the limitations of space.
2.2. References
Authors are responsible
for the accuracy and completeness of their references as these will not be checked by the editorial office.
References should be listed
alphabetically (see sample references) according to the "Harvard" system. Articles written by the same first author with different second
authors should be listed according to the second author's surname. Articles written by the same first author with more than one co-author
should be listed alphabetically according to the first author's surname and then according to the year of publication. Two or more references
to the same first author with the same publication year should have a, b, c, etc., suffixed to the year indicating the alphabetical order
of the second or third author, etc.
References to journals should contain the names and initials of the author(s), the year, the full
title, the abbreviation of the name of the periodical according to those in the Bibliographic Guide for Editors and Authors (American
Chemical Society, Washington, DC.) followed by the volume and page numbers.
References to books should include the title and name
and city of the publisher.
References in the text should be cited by the author's name and the year of publication. For 3 or more authors
the name of the first author followed by et al. should be used, e.g., Davis, Robinson (1990) or (Davis, Illum, 1984; de Ber et al., 1988,
1989; Borchardt et al., 1990, 1991a,b,c).
Journals:
Fagerholm, U., Lennernas, H., 1995. Experimental estimation of the
effective unstirred water layer thickness in the human jejunum and its importance in oral drug absorption. Eur. J. Pharm. Sci. 3, 247-253.
Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 1997. Experimental and computational approaches to estimate solubility and
permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 23, 3-25.
Books:
Alderborn, G., Nystrom,
C., 1998. Pharmaceutical Powder Compaction Technology. Marcel Dekker, New York.
Kissel, T., Koneberg, R., 1996. Injectable biodegradable
microspheres for vaccine delivery. In: Cohen, S. and Bernstein, H. (Eds.), Microparticulate systems for the delivery of proteins and
vaccines. Marcel Dekker, New York, pp. 51-87.
Unpublished observations, personal communications and manuscripts in preparation or
submitted for publication may be referred to in the text but should not appear in the list of references. Manuscripts in press (i.e.,
accepted for publication) may be included in the references citing the DOI article identifier, which enables the citation of a paper
before volume, issue and page numbers are allocated. The name of the journal in which they are to appear must be given.
Articles
in Special Issues: Please ensure that the words 'this issue' are added (in the list and text) to any references to other
articles in this Special Issue.
2.3. Illustrations
The number of illustrations should be limited to the essential.
(a) It is important to allow for reduction to fit a single column, 8.4 cm wide or at most a double column, maximally 17.6 cm wide. Of
preference, illustrations, especially photomicrographs, should be submitted in their final size (single or double column). When possible,
all key symbols should be explained in the figures. All letters and numerals appearing in a particular illustration should be of the
same size (approximately 1.4-2.0 mm height when reduced to 8.4 cm width). Comparable illustrations should carry letters, figures and
numerals of the same size when reduced to 8.4 cm width.
(b) Graphs should be prepared by a skilled photographer so that the dark,
cross-hatched background is eliminated, the faint portions of the graphs are intensified, and a sharp print is obtained. This process
may be avoided by using blue-ruled instead of black-ruled recording paper for the originals.
(c) Drawings of chemical structures
should as far as possible be produced with the use of a drawing program such as ChemDraw. Authors using the current versions of ChemDraw,
ChemIntosh and ChemWindows should use the JOC format.
(d) A calibration bar should be drawn on the micrographs instead of giving a
magnification factor in the figure legend.
(e) All illustrations should be referred to as figures and numbered in Arabic numerals
(Fig. 1, 2, etc.).
(f) Legends to figures should make the figures comprehensible without reference to the text.
(g) If, together
with your accepted article, you submit usable colour figures then Elsevier will ensure, at no additional charge, that these figures will
appear in colour on the web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in
colour in the printed version. For colour reproduction in print, you will receive information regarding the total cost from Elsevier
after receipt of your accepted article. The 2006 color prices are EUR 285.00 for the first page and EUR 191.00 for subsequent pages.
In some cases, color costs may be waived at the discretion of the Editor-in-Chief. For more detailed instructions please visit our artwork
instruction pages at http://www.elsevier.com/artworkinstructions.
Please note: Because of technical complications which
can arise by converting colour figures to 'grey scale' (for the printed version should you not opt for colour in print) please submit
in addition usable black and white prints corresponding to all the colour illustrations.
2.4. Tables
Tables should be prepared
for use in a single column (8.4 cm wide) or be of page width (17.6 cm).
(a) Each table should have a brief explanatory heading and
sufficient experimental detail (following the table body as a footnote) so as to be intelligible without reference to the text.
(b)
Tables should not duplicate material in text or illustrations.
(c) Short or abbreviated column headings should be used and, if necessary,
explained in footnotes, and indicated as a, b, c, etc.
(d) Statistical measures of variation, S.D.,
S.E., etc. should be identified.
(e) Tables should be numbered separately in Arabic numerals (Table 1, 2, etc.).
2.5. Formulas
and equations
Structural chemical formulas, process flow diagrams and complicated mathematical expressions should be very clearly
presented. All subscripts, superscripts, Greek letters and unusual characters must be identified. Structural chemical formulas and process
flow diagrams should be prepared in the same way as graphs.
2.6. GenBank accession numbers
Gene accession numbers refer
to genes or DNA sequences about which further information can be found in the databases at the National Center for Biotechnical Information
(NCBI) at the National Library of Medicine. Authors wishing to enable other scientists to use the accession numbers cited in their papers
via links to these sources, should reference this information in the following manner:
For each and every accession number
cited in an article, authors should type the accession number in
bold, underlined text
. Letters in the accession number
should always be capitalised. (See Example 1 below.) This combination of letters and format will enable Elsevier's typesetters to recognize
the relevant texts as accession numbers and add the required link to GenBank's sequences.
Example 1: "GenBank accession nos.
AI631510
,
AI631511
,
AI632198
, and
BF223228
), a B-cell tumor from a chronic lymphatic leukemia (GenBank
accession no.
BE675048
), and a T-cell lymphoma (GenBank accession no.
AA361117
)".
Authors are encouraged
to check accession numbers used very carefully. An error in a letter or number can result in a dead link.
In the final version
of the
printed article, the accession number text will not appear bold or underlined (see Example 2 below).
Example
2: "GenBank accession nos. AI631510, AI631511, AI632198, and BF223228), a B-cell tumor from a chronic lymphatic leukemia (GenBank
accession no. BE675048), and a T-cell lymphoma (GenBank accession no. AA361117)".
In the final version of the
electronic
copy, the accession number text will be linked to the appropriate source in the NCBI databases enabling readers to go directly to
that source from the article (see Example 3 below).
Example 3: "GenBank accession nos. AI631510, AI631511, AI632198,
and BF223228), a B-cell tumor from a chronic lymphatic leukemia (GenBank accession no. BE675048), and a T-cell lymphoma
(GenBank accession no. AA361117)".
2.7. Preparation of supplementary data
Elsevier now accepts electronic supplementary
material (e-components) to support and enhance your scientific research. Supplementary files offer the author additional possibilities
to publish supporting applications, movies, animation sequences, high-resolution images, background data sets, sound clips and more.
Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including
ScienceDirect (www.sciencedirect.com). In order to ensure that your submitted material is directly usable, please ensure that data is
provided in one of our recommended file formats. Authors should submit the material in electronic format together with the article and
supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at
http://www.elsevier.com/artworkinstructions.
2.8. Review articles
One page suggestions for comprehensive
reviews should be sent to the Editor-in-Chief at ejps-journal@helsinki.fi for consideration.
The manuscript of a review
article should be arranged as described for research articles (see sections 2.1 - 2.5) but according to the following sections: title
page, abstract and keywords (indexing terms, normally 3-6 items), Introduction, Specific sections determined by the author, Conclusions,
Acknowledgements, References, Figure legends and Figures, Tables. Sections ranging from the Introduction to the Conclusions should be
numbered. Subdivisions within a section should also be numbered within that section: 2.1., 2.2., 2.3. etc. All pages should be numbered
consecutively, the title page being p.1.
2.9. Commentaries and Mini-reviews
One page suggestions for commentaries and
mini-reviews should be sent directly to the Editor-in-Chief at ejps-journal@helsinki.fi for consideration. Please see
detailed information on commentaries and mini-reviews below.
2.9.1 Commentaries (Guidance)
The definition of a Commentary
for EJPS is three-fold. Firstly, it can be an argued piece of provocative scientific writing purporting to take a balanced position on
a controversial pharmaceutical science topic. A second option is for the author to approach the topic from a particular viewpoint on
one side of an argument. A third option is to provide a topical update on a hot topic in Pharmaceutical Sciences and this can be more
informative than controversial.
Commentaries will be commissioned by the editors in advance or invited from non-commissioned authors
if they wish to initially submit a one page summary of the intended Commentary to the editors in advance. All manuscripts will be assessed
by 2-3 independent referees.
The journal is looking for a stimulating and provoking essays, with referenced material, but without
an extensive reference list. Commentaries can contain one summary figure and/or table and shlould have no more than 30 references to
prefereably recent peer-reviewed material. The word count should be approximately 2,000 words maximum.
The commentary should have
a short abstract summary of 150 to 200 words and 4-5 key words should be included, The text should be broken down into 4-5 numbered
sections beginning with an Introduction and ending with a Conclusions section. A model of the structures is to be found in Eur. J. Pharm.
Sci. 19, 1-11 by R.D. Combes
2.9.2 Mini-review (Guidance)
Mini-reviews are thought provoking reviews of contemporary
pharmaceutical research. Themes are as described in the Scope of the Journal section.
Mini-reviews will usually be commissioned
by the editors in advance, but contributions are invited from non-commissioned authors if they wish to initially submit a one page summary
of the intended review to the editors in advance. All manuscripts will be assessed by 2-3 independent referees.
The structure of the
mini-review is as follows: a title page followed by a 200-300 word abstract with 4-5 key words. The text is then divided into numbered
sections finishing with a Summary section. References should be kept to a maximum of 60 and should be mostly to recent peer-reviewed
material. There is a combined maximum of 5 figures / tables. Authors are encouraged to submit their original unpublished work as part
of the review if appropriate. The total length of the review should be a maximum of 4,000 words.
3. Copyright guidelines for
authors
All authors must sign the "Transfer of Copyright" agreement before the article can be published. The transfer agreement
enables Elsevier to protect the copyrighted material for the authors, but does not relinquish the author's proprietary rights. The copyright
transfer covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform,
or any other reproductions of similar nature and translations, and includes the right to adapt the article for use in conjuction with
computer systems and programs, including reproduction or publication in machine-readable form and incorporation into retrieval systems.
Authors are responsible for obtaining from the copyright holder permission to reproduce any figures for which copyright exists. Transfer
of copyright agreement forms will be sent to the corresponding author following acceptance of the manuscript
4. Retained authors'
rights
As an author you (or your employer or institution) may do the following:
• make copies (print or electronic)
of the article for your own personal use, including for your own classroom teaching use
• make copies and distribute such copies
(including through e-mail) of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically,
e.g., via an e-mail list or list server)
• post a pre-print version of the article on Internet websites including electronic
pre-print servers, and to retain indefinitely such version on such servers or sites
• post a revised personal version of the
final text of the article (to reflect changes made in the peer review and editing process) on your personal or institutional website
or server, with a link to the journal homepage (on http://www.elsevier.com)
• present the article at a meeting or conference and to distribute copies of the article to the delegates attending such a meeting
• for your employer, if the article is a 'work for hire', made within the scope of your employment, your employer may use all
or part of the information in the article for other intra-company use (e.g., training)
• retain patent and trademark rights
and rights to any processes or procedure described in the article
• include the article in full or in part in a thesis or dissertation
(provided that this is not to be published commercially)
• use the article or any part thereof in a printed compilation of your
works, such as collected writings or lecture notes (subsequent to publication of your article in the journal)
• prepare other
derivative works, to extend the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full
acknowledgement of its original publication in the journal
5. Correcting proofs and reprints
Proofs will be sent to the
corresponding author. Elsevier is now sending PDF proofs by e-mail for correction. If an author is unable to handle this process, regular
print proofs will be sent. Elsevier will do everything possible to get the article corrected and published as quickly and accurately
as possible. Therefore, it is important to ensure that all corrections are sent back in ONE communication. Subsequent corrections will
not be possible. Only typesetting errors may be corrected; no changes in, or additions to, the accepted manuscript will be allowed.
Proofs should be returned to Elsevier within 48 hours.
EJPS has no page charges. Twenty-five offprints of each paper will
be supplied free of charge to the principal author. Additional offprints can be ordered on the offprint order form that accompanies the
copyright form.
6. Language Polishing: For authors, who require information about language editing and copyediting services
pre- and post-submission, please visit http://www.elsevier.com/wps/find/authorshome.authors/languagepolishing or contact authorsupport@elsevier.com for more information. Please note Elsevier neither endorses nor takes responsibility for any
products, goods or services offered by outside vendors through our services or in any advertising. For more information please refer
to our Terms & Conditions.
7. US National Institutes of Health (NIH) voluntary posting ("Public Access") policy
Elsevier facilitates author posting
in connection with the voluntary posting request of the NIH(referred to as the NIH "Public Access Policy"; see http://www.nih.gov/about/publicaccess/index.htm)
by posting the peer-reviewed author's manuscript directly to PubMed Central on request from the author, after formal publication. Upon
notification from Elsevier of acceptance, we will ask you to confirm via e-mail (by e-mailing us at NIHauthorrequest@elsevier.com)
that your work has received NIH funding (with the NIH award number, as well as the name and e-mail address of the Prime Investigator)
and that you intend to respond to the NIH request. Upon such confirmation, Elsevier will submit to PubMed Central on your behalf a version
of your manuscript that will include peer-review comments, for posting 12 months after the formal publication date. This will ensure
that you will have responded fully to the NIH request policy. There will be no need for you to post your manuscript directly with PubMed
Central, and any such posting is prohibited. Individual modifications to this general policy may apply to some Elsevier journals and
its society publishing partners.
8. Author enquiries
All questions arising after acceptance of a manuscript by the Editors,
especially those relating to proofs, publication and reprints, should be directed to the Publisher.
Elsevier Ireland Ltd
Brookvale
Plaza
East Park
Shannon, Co. Clare
Ireland
Tel: +353 61 709600
Fax: +353 61 709100
E-mail: authorsupport@elsevier.com
For enquiries relating to the submission of articles (including electronic submission where available) please visit this journal's homepage
at http://www.elsevier.com/journals. From here you can also track accepted articles ( http://www.elsevier.com/trackarticle)
and set up e-mail alerts to inform you of when an article's status has changed, as well as detailed artwork guidelines, copyright information,
frequently asked questions and more.
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property
as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas
contained in the material herein. Because of the rapid advances made in the medical sciences, independent verification of diagnoses
and drug doses should be made.
|
|
|
|
| |
| | |
|
| |
